• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

    3/13/24 6:16:13 AM ET
    $BGNE
    $CLOV
    $HCM
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BGNE alert in real time by email

    U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

    Shares of The Beauty Health Company (NASDAQ:SKIN) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter revenue results.

    Beauty Health posted quarterly loss of 7 cents per share, in-line with market estimates. The company’s quarterly sales came in at $96.80 million versus expectations of $87.63 million, according to data from Benzinga Pro.

    Beauty Health shares jumped 17.3% to $4.21 in pre-market trading.

    Here are some big stocks recording gains in today’s pre-market trading session.

    • HUTCHMED (China) Limited (NASDAQ:HCM) shares climbed 15% to $18.78 in pre-market trading after gaining 9% on Tuesday.
    • SIGA Technologies, Inc. (NASDAQ:SIGA) gained 13.5% to $6.04 in pre-market trading after the company reported a year-over-year increase in quarterly financial results.
    • BeiGene, Ltd. (NASDAQ:BGNE) shares climbed 13% to $185.00 in pre-market trading.
    • MaxCyte, Inc. (NASDAQ:MXCT) shares gained 10.5% to $4.40 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
    • Full Truck Alliance Co. Ltd. (NYSE:YMM) climbed 10.2% to $7.67 in pre-market trading. Full Truck Alliance announces extension of share repurchase program up to $300 million.
    • Legend Biotech Corporation (NASDAQ:LEGN) gained 9% to $71.00 in pre-market trading. Raymond James analyst Sean McCutcheon initiated coverage on Legend Biotech with an Outperform rating and announced a price target of $86.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) climbed 8% to $0.8290 in pre-market trading after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
    • United Natural Foods, Inc. (NYSE:UNFI) gained 2.7% to $11.86 in pre-market trading.

     

    Now Read This: Dollar Tree, Williams-Sonoma And 3 Stocks To Watch Heading Into Wednesday

    Don’t forget to check out our premarket coverage here

    Get the next $BGNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGNE
    $CLOV
    $HCM
    $LEGN

    CompanyDatePrice TargetRatingAnalyst
    Full Truck Alliance Co. Ltd.
    $YMM
    4/1/2026$8.00Underweight → Neutral
    Analyst
    United Natural Foods Inc.
    $UNFI
    3/26/2026$56.00Equal Weight → Overweight
    Wells Fargo
    Full Truck Alliance Co. Ltd.
    $YMM
    3/13/2026$9.00Buy → Neutral
    Daiwa Securities
    Legend Biotech Corporation
    $LEGN
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    Full Truck Alliance Co. Ltd.
    $YMM
    1/12/2026Neutral → Underweight
    Analyst
    United Natural Foods Inc.
    $UNFI
    1/8/2026Hold
    Deutsche Bank
    Legend Biotech Corporation
    $LEGN
    1/7/2026$75.00Outperform
    Oppenheimer
    More analyst ratings

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate ("ATTC") will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the

    4/8/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership

    WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with HealthEx, today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records and claims data, further advancing patients rights to access and share their own health data, which is central to federal interoperability efforts. Through HealthEx, Clover members can choose to connect their health information to tools like Claude so they can better understand and

    4/7/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Full Truck Alliance Co. Ltd. upgraded by Analyst with a new price target

    Analyst upgraded Full Truck Alliance Co. Ltd. from Underweight to Neutral and set a new price target of $8.00

    4/1/26 9:32:27 AM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    United Natural Foods upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded United Natural Foods from Equal Weight to Overweight and set a new price target of $56.00

    3/26/26 8:39:46 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    Full Truck Alliance Co. Ltd. downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Full Truck Alliance Co. Ltd. from Buy to Neutral and set a new price target of $9.00

    3/13/26 9:09:34 AM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lewis Sheri

    4 - Beauty Health Co (0001818093) (Issuer)

    4/13/26 4:27:04 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Monahan Michael P.

    4 - Beauty Health Co (0001818093) (Issuer)

    4/13/26 4:26:03 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ahuja Parmeet

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    4/10/26 4:45:56 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BGNE
    $CLOV
    $HCM
    $LEGN
    SEC Filings

    View All

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    4/9/26 6:19:32 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    4/9/26 6:06:12 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Natural Foods Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - UNITED NATURAL FOODS INC (0001020859) (Filer)

    4/2/26 8:02:27 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pappas James C bought $573,000 worth of shares (17,000 units at $33.71) (SEC Form 4)

    4 - UNITED NATURAL FOODS INC (0001020859) (Issuer)

    1/6/26 8:21:40 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Financials

    Live finance-specific insights

    View All

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SIGA Declares Special Cash Dividend of $0.60 Per Share

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the level of the special dividend declared in April 2025. The dividend is payable on April 23, 2026, to shareholders of record at the close of business on April 7, 2026. "Today's announcement of a special cash dividend reflects the strength of our balance sheet and focus on maximizing shareholder value," said Diem Nguyen, Chief Executive Officer. "We remain committed to executing our st

    3/26/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Full Truck Alliance Co. Ltd.

    SC 13G/A - Full Truck Alliance Co. Ltd. (0001838413) (Subject)

    12/3/24 4:30:33 PM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $BGNE
    $CLOV
    $HCM
    $LEGN
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

    Industry veteran brings two decades of platform commercialization experience in cell therapy, bioprocessing, and bioanalytics as Cellares prepares to support multiple clinical trials in 2026 Appointment follows five global manufacturing agreements with partners, including Bristol Myers Squibb, Kite, and leading academic institutions, as well as the FDA's first Advanced Manufacturing Technology designation for a cell therapy manufacturing platform. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ:MXCT) an

    12/1/25 9:00:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care